Imutex's Universal Flu Vaccine Inches Forward On New Data
Executive Summary
The Imutex joint venture between hVIVO and the SEEK Group updates promise of its universal flu vaccine candidate after additional data from a Phase IIb study showed a statistically significant effect on its primary endpoint.
You may also be interested in...
ConserV Bioscience: Getting Ahead Of New COVID-19 Strains
The SEEK spin-out ConserV Bioscience is developing a broad-spectrum coronavirus vaccine, aiming to get ahead of the arrival of new strains of the virus.
European Loan Funds F2G's Late-Stage Novel Antifungal
€24m loan from the European Investment Bank with match funding will progress Phase IIb antifungal Olorofim in invasive aspergillosis. CFO Ralf Schmid goes into details with Scrip.
Universal Flu Vaccine Is Still Several Years Away, Fauci Says
Developing a universal flu vaccine will be iterative process, National Institute of Allergy and Infectious Diseases Anthony Fauci says.